5 Best Get Rich Quick Stocks to Buy Right Now

2. Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Upside Potential as of July 2, 2026: 199.40%

On June 18, Mizuho lowered the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $4, down from $6. This came after the company’s negative Phase 3 KOASTAL-2 and -3 study outcomes. The firm has now removed navacaprant for depression from its financial model.

While highlighting the company’s pipeline, Mizuho reiterated an Outperform rating on Neumora Therapeutics, Inc. (NASDAQ:NMRA). Although still in early stages, the pipeline is “highly intriguing,” the analyst said. The company is developing NMRA-511, which is currently in Phase 1b clinical trials for Alzheimer’s disease agitation, as well as NMRA-861 and NMRA-898.

The firm’s model incorporates contributions from the clinical-stage assets. With that said, Mizuho anticipates critical updates for each program in the latter half of this year. The Street projects an upside potential of 199.40% for Neumora Therapeutics, Inc. (NASDAQ:NMRA), making it one of the best get rich quick stocks to buy right now.

The company also saw price cuts from two other firms. On June 16, Needham trimmed the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $5 from $8 and reaffirmed a Buy rating. On the same day, H.C. Wainwright also reduced the price target on the company from $18 to $7. The firm maintained a Buy rating.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a Massachusetts-based clinical-stage biopharmaceutical company that develops therapeutic solutions for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.